Referred to the House Committee on Energy and Commerce.
Amends the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353(b)) to state that the term “practitioner” can include artificial intelligence and machine learning technologies. Such AI/ML systems qualify only if (A) authorized to prescribe under the relevant State statute and (B) approved, cleared, or authorized by the FDA under sections 510(k), 513, 515, or 564.
Progressive demands strict privacy, bias audits; conservatives emphasize innovation.
Relative to its intended legislative type, this bill makes a concise substantive change by amending the FD&C Act to include AI/ML technologies as eligible practitioners for prescribing drugs contingent on state authorization and FDA authorization/clearance.
Amends the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353(b)) to state that the term “practitioner” can include artificial intelligence and machine learning technologies.
Such AI/ML systems qualify only if (A) authorized to prescribe under the relevant State statute and (B) approved, cleared, or authorized by the FDA under sections 510(k), 513, 515, or 564.
The change clarifies that state authorization plus FDA device/authorization pathways can permit AI-driven prescribing.
Content is narrow and low-cost so plausible path exists, but novel safety, liability, and oversight questions lower odds of rapid enactment.
Relative to its intended legislative type, this bill makes a concise substantive change by amending the FD&C Act to include AI/ML technologies as eligible practitioners for prescribing drugs contingent on state authorization and FDA authorization/clearance. The drafting is short and integrates with existing FDA device authorities but is mechanically terse and contains drafting ambiguities.
Progressive demands strict privacy, bias audits; conservatives emphasize innovation.
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressive demands strict privacy, bias audits; conservatives emphasize innovation.
Likely cautiously receptive to regulated AI tools that expand access, but concerned about safety, equity, and corporate control.
Would want strong patient protections, transparency, and enforceable anti‑bias and privacy safeguards before supporting broad deployment.
Views the bill as a measured clarification balancing state authority and FDA review to enable AI prescribing.
Sees benefits in legal certainty and innovation but wants clearer rules on liability, oversight, and post‑market safety monitoring.
Generally favorable because it enables innovation and respects state authority to authorize prescribers, while relying on FDA authorization pathways.
May still press for streamlined approvals and clear liability rules to avoid chilling deployment.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Content is narrow and low-cost so plausible path exists, but novel safety, liability, and oversight questions lower odds of rapid enactment.
The bill has not accumulated any surfaced votes yet.
Progressive demands strict privacy, bias audits; conservatives emphasize innovation.
Content is narrow and low-cost so plausible path exists, but novel safety, liability, and oversight questions lower odds of rapid enactment.
Relative to its intended legislative type, this bill makes a concise substantive change by amending the FD&C Act to include AI/ML technologies as eligible practitioners for prescribing drugs contingent on state authoriz…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.